Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety ...

ASCO: new Sarclisa data support subcutaneous administration with on-body injector . New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via a ...

For the first time in Canada, a patient has received cancer immunotherapy by subcutaneous (under the skin) injection in their ...

New formulation supports adaptable care delivery in oncology settings with limited capacity or remote patient populations ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that its commercial partner in Japan, Yoshindo Inc., has launched Ustekinumab ...

On May 13 2025 Governor Scott signed a bill to allow a safe injection site in Burlington Vermont. This site will not allow police officers to take any action and there is no age limit on who can use ...